
Feature|Videos|July 14, 2025
Strategies in Today’s Market for Pricing and Reimbursement Models
A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models that require strong value propositions, strategic planning, and significant upfront investment in data and stakeholder alignment.
Advertisement
Episodes in this series

In this episode, the panelists provide a candid look at how payers are increasingly open to innovative reimbursement structures—but only if the groundwork is thoughtfully laid. It’s not enough to pitch a novel payment model; manufacturers must bring solutions tied to the payer’s biggest challenges and be ready to share risk.
Key discussion topics include:
- Designing outcome-based contracts aligned with payer data systems.
- When and how to engage payer medical directors in model design.
- Differences in feasibility across pharmacy and medical benefit products.
- Why a strong value proposition must precede any innovative contract.
Advertisement
Related to this article

FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.

Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.

FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.

Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.

Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.

Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.

Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
The Battle to Own the GLP-1 Patient Journey
3
Novo Announces Drug Discovery Collaboration with Anthropic
4
Understanding the Latest with MFN Pricing and What It Means to Pharma
5

